Cargando…
First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of (68)Ga-PSMA-11 (n = 2) and (68)Ga-DOTA-TOC (n = 1...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953571/ https://www.ncbi.nlm.nih.gov/pubmed/36831181 http://dx.doi.org/10.3390/biomedicines11020645 |
_version_ | 1784893910801186816 |
---|---|
author | Muraglia, Lorenzo Mattana, Francesco Travaini, Laura Lavinia Musi, Gennaro Bertani, Emilio Renne, Giuseppe Pisa, Eleonora Ferrari, Mahila Esmeralda Fumagalli Romario, Uberto De Cobelli, Ottavio Fusco, Nicola Ceci, Francesco |
author_facet | Muraglia, Lorenzo Mattana, Francesco Travaini, Laura Lavinia Musi, Gennaro Bertani, Emilio Renne, Giuseppe Pisa, Eleonora Ferrari, Mahila Esmeralda Fumagalli Romario, Uberto De Cobelli, Ottavio Fusco, Nicola Ceci, Francesco |
author_sort | Muraglia, Lorenzo |
collection | PubMed |
description | Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of (68)Ga-PSMA-11 (n = 2) and (68)Ga-DOTA-TOC (n = 1), respectively. Patients were administrated with PET radiopharmaceuticals to perform radio-guided surgery with a beta-probe detector during radical prostatectomy for prostate cancer (PCa) and salvage lymphadenectomy for recurrent neuroendocrine tumor (NET) of the ileum, respectively. All procedures have been performed within two ongoing clinical trials in our Institute (NCT05596851 and NCT05448157). Pathologic assessment with immunohistochemistry (PSMA-staining and SSA immunoreactivity) was considered as standard of truth. Specimen images were compared with baseline PET/CT images and histopathological analysis. Results: Patients received 1 MBq/Kg of (68)Ga-PSMA-11 (PCa) or 1.2 MBq/Kg of (68)Ga-DOTA-TOC (NET) prior to surgery. Specimens were collected, positioned in the dedicated specimen container, and scanned to obtain high-resolution PET/CT images. In all cases, a perfect match was observed between the findings detected by the specimen imager and histopathology. Overall, the PET spatial resolution was sensibly higher for the specimen images compared to the baseline whole-body PET/CT images. Furthermore, the use of the PET/CT specimen imager did not significantly interfere with any procedures, and the overall length of the surgery was not affected using the PET/CT specimen imager. Finally, the radiation exposure of the operating theater staff was lower than 40 µSv per procedure (range 26–40 μSv). Conclusions: the image acquisition of specimens obtained by patients who received intra-surgery injections of (68)Ga-PSMA-11 and (68)Ga-DOTA-TOC was feasible and reliable also in a live-experience session and has been easily adapted to surgery daily practice. The high sensitivity, together with the evaluation of intra-lesion tumor heterogeneity, were the most relevant results since the data derived from specimen PET/CT imaging matched perfectly with the histopathological analysis. |
format | Online Article Text |
id | pubmed-9953571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99535712023-02-25 First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor Muraglia, Lorenzo Mattana, Francesco Travaini, Laura Lavinia Musi, Gennaro Bertani, Emilio Renne, Giuseppe Pisa, Eleonora Ferrari, Mahila Esmeralda Fumagalli Romario, Uberto De Cobelli, Ottavio Fusco, Nicola Ceci, Francesco Biomedicines Article Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of (68)Ga-PSMA-11 (n = 2) and (68)Ga-DOTA-TOC (n = 1), respectively. Patients were administrated with PET radiopharmaceuticals to perform radio-guided surgery with a beta-probe detector during radical prostatectomy for prostate cancer (PCa) and salvage lymphadenectomy for recurrent neuroendocrine tumor (NET) of the ileum, respectively. All procedures have been performed within two ongoing clinical trials in our Institute (NCT05596851 and NCT05448157). Pathologic assessment with immunohistochemistry (PSMA-staining and SSA immunoreactivity) was considered as standard of truth. Specimen images were compared with baseline PET/CT images and histopathological analysis. Results: Patients received 1 MBq/Kg of (68)Ga-PSMA-11 (PCa) or 1.2 MBq/Kg of (68)Ga-DOTA-TOC (NET) prior to surgery. Specimens were collected, positioned in the dedicated specimen container, and scanned to obtain high-resolution PET/CT images. In all cases, a perfect match was observed between the findings detected by the specimen imager and histopathology. Overall, the PET spatial resolution was sensibly higher for the specimen images compared to the baseline whole-body PET/CT images. Furthermore, the use of the PET/CT specimen imager did not significantly interfere with any procedures, and the overall length of the surgery was not affected using the PET/CT specimen imager. Finally, the radiation exposure of the operating theater staff was lower than 40 µSv per procedure (range 26–40 μSv). Conclusions: the image acquisition of specimens obtained by patients who received intra-surgery injections of (68)Ga-PSMA-11 and (68)Ga-DOTA-TOC was feasible and reliable also in a live-experience session and has been easily adapted to surgery daily practice. The high sensitivity, together with the evaluation of intra-lesion tumor heterogeneity, were the most relevant results since the data derived from specimen PET/CT imaging matched perfectly with the histopathological analysis. MDPI 2023-02-20 /pmc/articles/PMC9953571/ /pubmed/36831181 http://dx.doi.org/10.3390/biomedicines11020645 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Muraglia, Lorenzo Mattana, Francesco Travaini, Laura Lavinia Musi, Gennaro Bertani, Emilio Renne, Giuseppe Pisa, Eleonora Ferrari, Mahila Esmeralda Fumagalli Romario, Uberto De Cobelli, Ottavio Fusco, Nicola Ceci, Francesco First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor |
title | First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor |
title_full | First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor |
title_fullStr | First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor |
title_full_unstemmed | First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor |
title_short | First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor |
title_sort | first live-experience session with pet/ct specimen imager: a pilot analysis in prostate cancer and neuroendocrine tumor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953571/ https://www.ncbi.nlm.nih.gov/pubmed/36831181 http://dx.doi.org/10.3390/biomedicines11020645 |
work_keys_str_mv | AT muraglialorenzo firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT mattanafrancesco firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT travainilauralavinia firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT musigennaro firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT bertaniemilio firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT rennegiuseppe firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT pisaeleonora firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT ferrarimahilaesmeralda firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT fumagalliromariouberto firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT decobelliottavio firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT fusconicola firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor AT cecifrancesco firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor |